Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus GP induction chemotherapy followed by concurrent chemoradiotherapy and metronomic capecitabine maintenance in stage III-IVA nasopharyngeal carcinoma
ChiCTR2300076245Phase 2Not yet recruiting
- Sponsor
- Neijiang Second People's Hospital
- Start
- Sep 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab, gemcitabine, cisplatin and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Neijiang Second People's Hospital. Primary endpoints: Complete remission rate and Objective response rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
penpulimabgemcitabinecisplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300076245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076245.